Neurinnov

Neurinnov operates in a specialized segment of medical devices focused on implantable neurostimulation for severe spinal cord injury. Its stated initial use case is restoring hand-grasping function for people with complete tetraplegia, rather than offering a broad neuromodulation platform for general pain management or wellness applications. The differentiator is selective electrical-current steering through one or more specific nerves, intended to activate targeted muscle groups while reducing simultaneous activation of associated muscles. The company also combines device design, development, and commercialization services, which may provide a broader engineering capability than a single-product clinical venture. Its position is supported by a reported five granted patents, a €3.42 million total funding base, and clinical evidence describing functional grasping tasks during a 28-day implantation period. Comparisons with named competitors would therefore be unreliable. Relative to the wider medical-device and neurotechnology markets, Neurinnov appears to be an early-stage, clinically focused specialist whose differentiation depends on selective nerve targeting and restoration of upper-limb autonomy.

Founded in 2018 as a spin-off associated with INRIA and the University of Montpellier, the company secured a €3 million seed round on Dec 12, 2021. That financing was followed by several patent activities, including an active implantable medical device filing dated Sep 24, 2021 and additional neural-stimulation filings dated Jul 29, 2022 and Dec 8, 2022. A €25,000 grant announced on Jan 31, 2023 brought total recorded funding to approximately $3.42 million. The product focus has remained consistent: an ASIC Neural Stimulation Platform designed to selectively activate nerve fascicles and support hand grasping for patients with complete tetraplegia. Clinical demonstrations of holding a can and drinking through a straw indicate movement beyond laboratory stimulation toward practical functional outcomes. At the same time, there is no documented employee-growth series, hiring plan, regulatory approval, large-scale clinical program, product launch, or post-2023 financing. The trajectory therefore suggests continued technology and clinical development, with commercialization timing and scale still uncertain.